Cargando…

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations

PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the PTEN gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodón, Jordi, Funchain, Pauline, Laetsch, Theodore W, Arkenau, Hendrik-Tobias, Hervieu, Alice, Singer, Christian F, Murciano-Goroff, Yonina R, Chawla, Sant P, Anthony, Kristin, Yamamiya, Ikuo, Liu, Mei, Halim, Abdel-Baset, Benhadji, Karim A, Takahashi, Osamu, Delaloge, Suzette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2022
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334253/ https://www.ncbi.nlm.nih.gov/pubmed/36039910 http://dx.doi.org/10.2217/fon-2022-0305

Ejemplares similares

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
por: Piha-Paul, Sarina A., et al.
Publicado: (2021)

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
por: Lee, Jii Bum, et al.
Publicado: (2021)

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
por: Bahleda, R., et al.
Publicado: (2020)

Medical oncologists’ willingness to participate in bundled payment programs
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2018)

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
por: Goldman, Jonathan W., et al.
Publicado: (2023)

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
por: Bendell, Johanna C., et al.
Publicado: (2016)

Shieldings: TAS
Publicado: (2004)

Shieldings: TAS
Publicado: (2004)

Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations
por: Kingston, Belinda, et al.
Publicado: (2019)

TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
por: Ueno, Hiroyuki, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Vanillin Activates Human Bitter Taste Receptors TAS2R14, TAS2R20, and TAS2R39
por: Morini, Gabriella, et al.
Publicado: (2021)

A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines
por: Hesson, Luke B, et al.
Publicado: (2012)

Tas chebal : jun chajp a'tel pajbil /
por: González Dillon, Mónica
Publicado: (2013)

Formation of $^{117}In-H$ pairs after annealing of GaN implanted with $^{117}Cd(^{117}In)$
por: Dietrich, M, et al.
Publicado: (2001)

Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system
por: Feunteun, Jean, et al.
Publicado: (2022)

Decay study of the $^{117}$Cs and $^{117}$Xe nuclei
por: Marguier, G, et al.
Publicado: (1985)

Energy Deposition in the Triplet and TAS Issues
por: Broggi, F
Publicado: (2008)

Implementation of TasP: challenges and opportunities
por: Lange, Joep
Publicado: (2014)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Tunable Contact Types and Interfacial Electronic Properties in TaS(2)/MoS(2) and TaS(2)/WSe(2) Heterostructures
por: Zhu, Xiangjiu, et al.
Publicado: (2023)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

Members of Bitter Taste Receptor Cluster Tas2r143/Tas2r135/Tas2r126 Are Expressed in the Epithelium of Murine Airways and Other Non-gustatory Tissues
por: Liu, Shuya, et al.
Publicado: (2017)

Enhanced superconductivity in atomically thin TaS(2)
por: Navarro-Moratalla, Efrén, et al.
Publicado: (2016)

Raman Optical Activity of 1T-TaS(2)
por: Lacinska, Ewa M., et al.
Publicado: (2022)

Women are credited less in science than men
por: Ross, Matthew B., et al.
Publicado: (2022)

Author Correction: Women are credited less in science than men
por: Ross, Matthew B., et al.
Publicado: (2023)

miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian cancer stem cells by targeting PTEN
por: Gao, Zubiao, et al.
Publicado: (2021)

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells
por: Jin, Hui, et al.
Publicado: (2013)

A functional comparison of the domestic cat bitter receptors Tas2r38 and Tas2r43 with their human orthologs
por: Sandau, Michelle M, et al.
Publicado: (2015)

Genes from the TAS1R and TAS2R Families of Taste Receptors: Looking for Signatures of Their Adaptive Role in Human Evolution
por: Valente, Cristina, et al.
Publicado: (2018)

Evaluation of the association between the TAS1R2 and TAS1R3 variants and food intake and nutritional status in children
por: Melo, Silvia V., et al.
Publicado: (2017)

Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists
por: Grassin-Delyle, Stanislas, et al.
Publicado: (2019)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
por: Yamamoto, Nobuyuki, et al.
Publicado: (2020)

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2022)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h1b5416upf0qlo0lvvv66qokks